India is launching low cost, weight-loss medication and Novo Nordisk is betting on its manufacturers to remain on prime

The primary wave of generic variations of Novo Nordisk’s GLP-1 weight-loss medication launched in India over the weekend, with a minimum of 5 home drugmakers undercutting the unique value by as much as 80%. It comes because the Danish drugmaker’s patent expired on Friday, with the corporate preventing to take care of its lead within the profitable market. 

India is a essential market, with round 100 million individuals residing with diabetes and practically 1 / 4 categorized as overweight. The nation is also called “the world’s pharmacy” with its well-developed generic medication business supplying round 20% of world off‑patent medicines. 

Solar Pharmaceutical, one of many prime generics producers on the planet, on Saturday launched a generic semaglutide for as little as 750 rupees ($8) for a weekly injection, or about 3,400 rupees per 30 days. That compares with Novo’s retail value of between 8,800 and 10,000 rupees in India, relying on the dosage.

In the meantime, export-focused Dr. Reddy’s Laboratories has up to now launched semaglutide for treating diabetes at round 4,200 rupees per 30 days and plans to develop to Canada, Turkey and Brazil this yr. 

The corporate’s aim is to democratize entry to GLP-1 medication worldwide, stated Deepak Sapra, CEO of Pharmaceutical Providers and API at Dr. Reddy’s, at a digital launch occasion on Saturday. It is concentrating on annual gross sales of 12 million semaglutide pens within the first yr of launch throughout all markets, together with India.

“That is one thing that Indian generic gamers have been getting ready for a really very long time,” Salil Kallianpur, an impartial pharma guide based mostly in India, advised CNBC.

Greater than 50 manufacturers are anticipated to launch generic variations of semaglutide within the coming months. That is a small quantity by Indian requirements, due to the relative complexity of constructing such medication with their extra stringent qc, Kallianpur stated.

At the same time as semaglutide stays protected against generic competitors within the U.S. – its largest market by far– till 2032, patent expirations in India, Canada, Brazil, and China this yr are prone to have a large affect on its income. In February, Novo warned that gross sales might decline by 5% to 13% in 2026.

Novo is already dealing with declining market share amid fierce competitors from Eli Lilly and different drugmakers. U.S. President Donald Trump has additionally pushed for decrease drug costs, and a November cope with the administration slashed GLP-1 costs within the nation. It’s unclear whether or not greater gross sales volumes will offset the decrease costs.

In December final yr, Novo lowered the value of Wegovy by 37% from its launch value in India, earlier than its patent expired, Reuters reported.

Analysts advised CNBC that Novo wants to chop costs in India to defend its market share. Vishal Manchanda, a pharma sector analyst at Systematix Group, stated that Novo might retain a massive share of the market if it maintains a 15%–20% premium over generic variations.

Generic entries will have an effect on Novo’s gross sales in India, nevertheless it’s not but clear whether or not the Danish drugmaker will lose its main place, stated Sydbank analyst Søren Løntoft Hansen. 

Novo has traditionally maintained a number one market share regardless of dropping patent safety. The corporate has been a number one producer of insulin since its inception a century in the past, and it has continued to dominate the market whereas nonetheless promoting at a premium to generic rivals. Generic producers have struggled to scale up manufacturing to problem Novo’s dominance, Hansen stated.

Novo is assured in its capability to retain customers in India. “Our dimension, expertise, and full care ecosystem justify the value we’re getting after a 37% discount,” Vikrant Shrotriya, managing director of Novo Nordisk India, advised CNBC’s “Inside India” on Friday.

Though Novo launched well-liked weight problems drug Wegovy and diabetes remedy drug Ozempic in India after Lilly launched its rival Mounjaro and Zepbound, it “transformed a mistake into a chance,” because it got here in at a a lot lower cost and is now launching second manufacturers, Kallianpur stated.

Wegovy is being launched as Poviztra by means of a partnership with Emcure Pharma, whereas Ozempic is being marketed as Extensior in collaboration with Abbott India. These companions deliver deep ties to pharmacies and physicians throughout the nation, enhancing the drugmaker’s attain.

It is a basic technique for safeguarding a premium model in opposition to cheaper generics, Kallianpur stated, including that Novo is banking closely on its fame. “The model is basically the moat.”

Whereas Solar Pharma and Dr. Reddy’s launched semaglutide at about 50% under Novo’s authentic costs, smaller domestic-focused producers equivalent to Natco Pharma and Alkem Laboratories are providing steeper reductions of practically 80%.

Natco Pharma’s vial formulation is priced at 1,250 rupees per 30 days, making it probably the most reasonably priced choices in the marketplace, whereas Alkem Laboratories has launched the lowest-priced prefilled semaglutide injections beginning at 1,800 rupees per 30 days.

By means of a mixture of reasonably priced pricing and “in depth distribution throughout smaller cities in India, Alkem goals to “make this product accessible to extra sufferers who want it,” the corporate’s CEO Vikas Gupta advised CNBC in an electronic mail.

Gross sales of GLP‑1 medication within the nation have risen quickly, with the transferring annual turnover in February rising 178% from a yr earlier to 14.46 billion rupees, in keeping with information from Indian market intelligence agency Pharmarack.

Regardless of the rising reputation of those GLP-1 medication in India, the value stays a key deterrent. Rajiv Kovil, a diabetes specialist, stated practically 50% of his sufferers may gain advantage from GLP-1 medication, however solely 5% are at present utilizing them.

There is no such thing as a official indication from Novo or Eli Lilly on a recent spherical of value cuts, acknowledged the Mumbai-based diabetologist, however stated that “Novo will chunk the bullet ultimately.”

In the meantime, he plans to attend for extra proof on the effectiveness and availability of the brand new generics earlier than switching his sufferers from Novo’s and Lilly’s GLP-1 medication.

GLP-1 medication equivalent to semaglutide are peptide-based medicines that require specialised expertise for manufacturing and distribution, together with a chilly chain for storage, making them extra advanced to fabricate. That is in contrast to most medication manufactured in India, equivalent to painkillers and antibiotics.

“It’s important to pay actually good consideration to high quality management, as a result of these molecules are far more advanced than aspirin, for instance,” Knud Jensen, a chemistry professor on the College of Copenhagen and President of the European Peptide Society, advised CNBC.

“High quality management for these massive molecules is tougher than for small molecules,” he stated. “The molecule that’s given to sufferers needs to be excellent, and it can not have any aspect merchandise or contaminants.”

Kallianpur, nevertheless, stated that many underestimate the progress of Indian drug producers over the previous 10 years. 

“They’ve understood that compliance is at this time not a value, however it may be transformed into a really helpful moat,” he stated. “That may be a huge mindset shift that’s taking place in India.”

Consultants, nevertheless, nonetheless largely agree that regardless of progress, high quality management in India remains to be catching up with Europe or the U.S.

There’s additionally concern amongst some business watchers that generic semaglutide might turn into obtainable in markets the place the drug remains to be patent-protected. “If India is beginning to manufacture GLP-1s at a big scale, that won’t all keep in India, no matter corporations strive, nations attempt to stop it from coming in,” Ben van der Schaaf, Associate at Arthur D. Little, advised CNBC. “It is huge enterprise.”

Jyske Financial institution analyst Henrik Hallengreen Laustsen says that if the legal guidelines are adopted and semaglutide is bought solely in nations the place the patent has expired, Novo would be capable of preserve its market dominance.